Related Experiment Video
Updated: Aug 9, 2026
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
Initial experiences of removal of intra-aortic balloon pumps with the Angio-Seal
Koji Kato1, Naoki Sato, Takeshi Yamamoto
1Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan.
Insights
Angio-Seal effectively and safely achieved hemostasis after intra-aortic balloon pump removal in 16 patients. No major or minor complications were observed within seven days, demonstrating its utility in vascular hemostasis.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
Background:
- Angio-Seal is a proven vascular hemostasis device for cardiac catheterization.
- Its efficacy in intra-aortic balloon pump (IABP) removal is not well-established.
Purpose of the Study:
- To evaluate the safety and effectiveness of Angio-Seal for hemostasis after IABP removal.
Main Methods:
- A prospective study involving 16 patients undergoing IABP removal.
- Angio-Seal device was used for achieving hemostasis.
- Safety endpoint included major (e.g., retroperitoneal bleeding, vessel occlusion) and minor (e.g., hematoma, pseudoaneurysm) complications within 7 days.
Main Results:
- Rapid hemostasis was achieved, with a mean time of 3.3 minutes (range 2-5 minutes).
- No major complications were recorded.
- No minor complications, including hematoma, AV fistula, or pseudoaneurysm, were observed within the 7-day follow-up period.
Conclusions:
- Angio-Seal is a safe and effective device for achieving rapid hemostasis following IABP removal.
- It presents a viable alternative for vascular closure in this patient population.
Abstract:
Angio-Seal, a vascular hemostasis device, has been shown to be safe and effective in rapidly achieving hemostasis after cardiac catheterization or coronary intervention. We propose that similar results can be obtained with Angio-Seal when removing an intra-aortic balloon pump (IABP). We studied 16 patients in whom Angio-Seal was utilized in IABP removals. The primary safety endpoint was a composite of major complications such as retroperitoneal bleeding, vessel occlusion, loss of distal pulses, vascular surgery or death, and minor complications such as hematoma (> 10 cm), AV fistula or pseudoaneurysm by 7 days after removal. The time-to-hemostasis was 2-5 minutes (mean 3.3 minutes). There were no instances of major or minor complications by the seventh day in any patients.
